<DOC>
	<DOC>NCT01381731</DOC>
	<brief_summary>The objectives of this trial are to: - Assess the safety and tolerability of diquafosol tetrasodium ophthalmic solution versus placebo following one week of treatment in subjects undergoing photorefractive keratectomy (PRK). - Evaluate the potential of diquafosol to accelerate corneal wound healing/re-epithelialization following PRK.</brief_summary>
	<brief_title>A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>between age 18 45 years old candidate for bilateral PRK dry eye disease any corneal pathologies previous corneal or intraocular surgeries</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>post PRK wound healing</keyword>
</DOC>